Q BioMed Inc (QBIO)

[Seeking Alphaville]

The QBIO product roadmap provides key insight into the business model from which investors can extrapolate a future, tangible value range.

Diagnostic

Upon clearance or approval of the diagnostic kit, Q BioMed would charge a to-be-determined fee to the ophthalmologist for each assay and analysis. Since glaucoma is a lifelong disease, these swift tests will have to be performed on a routine basis on patients to preserve visual acuity and measure progression, it renders the kit as a recurring (and compounding) revenue stream for the physician and the Company. Considering 70 million are afflicted today, and millions more could be tested for measurement and progression at earlier intervals, it is reasonable to expect that one in three patients could regularly undergo this test, generating considerable revenue.